Oxidized lipoproteins and nitric oxide

Current Opinion in Lipidology

Volumn 7, Issue 5, 1996, Pages 274-280

  Jessup, Wendy ^a  

^a HEART RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIUM DERIVED RELAXING FACTOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDIZED LOW DENSITY LIPOPROTEIN; SCAVENGER;

ARTERY DISEASE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL TONE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; INTIMA; LIPID OXIDATION; MACROPHAGE; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION; VASCULAR ENDOTHELIUM;

LETHRINIDAE;

EID: 0029849574     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199610000-00003     Document Type: Review

References (73)

1. Henry PD, Cabello OA, Chen CH: Hypercholesterolemia and endothelial dysfunction. Curr Opin Lipidol 1995, 6:190-195.
2. Sorensen K, Celermajer D, Georgakopoulos D, Hatcher G, Betteridge J, Deanfield J: Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia, and is related to the Lp(a) level. J Clin Invest 1994, 93:50-55.
3. Anderson TJ, Gerhard MD, Meredith IT, Charbonneau F, Delagrange D, Creager MA, Selwyn AP, Ganz P: Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol 1995, 75:71B-74B.
4. Cohen RA: The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. Prog Cardiovasc Dis 1995, 38:105-128.
5. Loscalzo J, Welch G: Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 1995, 38:87-104.
6. Busse R, Fleming I: Regulation and functional consequences of endothelial nitric oxide formation. Ann Med 1995, 27:331-340.
7. Nava E, Noll G, Luscher TF: Nitric oxide in cardiovascular diseases. Ann Med 1995, 27:343-351.
8. Dusting GJ, Macdonald PS: Endogenous nitric oxide in cardiovascular disease and transplantation. Ann Med 1995, 27:395-406.
9. Dusting GJ: Nitric oxide in cardiovascular disorders. J Vasc Res 1995, 32:143-161.
10. Harrison DG, Ohara Y: Physiologic consequences of increased vascular oxidant stresses in hypercholesterolemia and atherosclerosis: implications for impaired vasomotion. Am J Cardiol 1995, 75:75B-81B. This review gives a comprehensive discussion of the likely relationships between superoxide release and EDRF activity in hypercholesterolemia and atherosclerosis.
11. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D: Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci U S A 1984, 81:3883-3887.
12. Glavind J, Hartmann S, Clemmesen J, Jessen KE, Dam H: Studies on the role of lipoperoxides in human pathology 2: the presence of peroxidized lipids in the atherosclerotic aorta. Acta Pathol 1952, 30:1-6.
13. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989, 320:915-924.
14. Stocker R: Lipoprotein oxidation: mechanistic aspects, methodological approaches and clinical relevance. Curr Opin Lipidol 1994, 5:422-433.
15. Lehr H, Hübner C, Nolte D, Finckh B, Beisiegel U, Kohlschütter A, Messmer K: Oxidatively modified human low-density lipoprotein stimulates leukocyte adherence to the microvascular endothelium in vivo. Res Exp Med 1991, 191:85-90.
16. Kritharides L, Jessup W, Mander E, Dean R: Apolipoprotein A-1 mediated efflux of sterols from oxidized LDL-loaded macrophages. Arterioscler Thromb Vasc Biol 1995, 15:276-289.
17. Clare K, Hardwick S, Carpenter K, Weerantunge N, Mitchinson M: Toxicity of oxysterols to human monocyte-macrophages. Atherosclerosis 1995, 118:67-75.
18. Suarna C, Dean RT, May J, Stocker R: Human atherosclerotic plaque contains both oxidized lipids and relatively large amounts of α-tocopherol and ascorbate. Arterioscler Thromb Vasc Biol 1995, 15: 1616-1624. This group compared the levels of oxidized lipids and antioxidants of normal and atheromatous human arteries, taking care to assess their recoveries during tissue processing. Atherosclerotic plaques were not deficient in the antioxidant vitamins C and E, despite the presence of large amounts of oxidized lipids.
19. Carpenter KL, Taylor SE, van der Veen C, Williamson BK, Ballantine JA, Mitchinson MJ: Lipids and oxidized lipids in human atherosclerotic lesions at different stages of development Biochim Biophys Acta 1995, 1256:141-150.
20. Brown A, Dean R, Jessup W: Free and esterified oxysterol: formation during copper-oxidation of low density lipoprotein and uptake by macrophages. J Lipid Res 1996, 37:320-335. In copper-oxidized LDL up to 50% of cholesterol is converted to oxysterols. Macrophage foam cells produced by uptake of oxidized LDL have a comparably high oxysterol content, the majority of which is esterified.
21. Steinbrecher UP, Lougheed M: Scavenger receptor-independent stimulation of cholesterol esterification in macrophages by low-density lipoprotein extracted from human aortic intima. Arterioscler Thromb 1992, 12:608-625.
22. Garner B, Jessup W: Cell-mediated oxidation of low-density lipoprotein: the elusive mechanism(s). Redox Reports 1996, 2:97-104.
23. Hazell L, Arnold L, Flowers D, Waeg G, Malle E, Stocker R: Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin Invest 1996, 97:1535-1544. A monoclonal antibody specific for hypochlorite-modified proteins stained atherosclerotic lesions more strongly than normal arteries, providing evidence for this oxidant in vivo. The staining was predominantly associated with cells (endothelial, macrophage and smooth muscle). Hemosiderin in macrophages was also observed.
24. Evans P, Smith C, Mitchinson M, Halliwell B: Metal ion release from mechanically-disrupted human arterial wall. Implications for the development of atherosclerosis. Free Rad Res 1995, 23:465-469. Comparison of 'catalytically active' iron and copper in homogenates of arteries finds no significant difference between normal and atherosclerotic lesions.
25. Minor RJ, Myers PR, Guerra RJ, Bates JN, Harrison DG: Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. J Clin Invest 1990, 86:2109-2116.
26. Kugiyama K, Kerns S, Morrisett J, Roberts R, Henry P: Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified lipoproteins. Nature 1990, 344:160-162.
27. Chin JH, Azhar S, Hoffman BB: Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest 1992, 89:10-18.
28. Galle J, Bengen J, Schollmeyer P, Wanner C: Impairment of endothelium-dependent dilation in rabbit renal arteries by oxidized lipoprotein(a). Role of oxygen-derived radicals. Circulation 1995, 92:1582-1589.
29. Shelton J, Kopczewski R: Nitric oxide induced free-radical reactions. J Am Chem Soc 1967, 32:2908-2910.
30. Rubbo H, Parthasarathy S, Barnes S, Kirk M, Kalyaranaraman B, Freeman B: Nitric oxide inhibition of lipoxygenase-dependent liposome and low-density lipoprotein oxidation: termination of radical chain propagation reactions and formation of nitrogen-containing oxidized lipid derivatives. Arch Biochem Biophys 1995, 324:15-25. NO solutions or NO donors partially inhibit lipoxygenase-catalysed lipid oxidation. Mass spectrometry of the products suggest formation of nitrogen-containing oxidized lipids and the authors suggest that NO* reacts directly with lipid peroxyl radicals as a chain-breaking antoxidant.
31. Mangin EJ, Kugiyama K, Nguy JH, Kerns SA, Henry PD: Effects of lysolipids and oxidatively modified low density lipoprotein on endothelium-dependent relaxation of rabbit aorta. Circ Res 1993, 72:161-166.
32. Plane F, Bruckdorfer KR, Kerr P, Steuer A, Jacobs M: Oxidative modification of low-density lipoproteins and the inhibition of relaxations mediated by endothelium-derived nitric oxide in rabbit aorta. Br J Pharmacol 1992, 105:216-222.
33. Ohara Y, Peterson TE, Zheng B, Kuo JF, Harrison DG: Lysophosphatidylcholine increases vascular superoxide anion production via protein kinase C activation. Arterioscler Thromb 1994, 14:1007-1013.
34. Ohara Y, Peterson T, Harrison D: Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993, 91: 2546-2551.
35. Ohara Y, Peterson TE, Sayegh HS, Subramanian RR, Wilcox JN, Harrison DG: Dietary correction of hypercholesterolemia in the rabbit normalizes endothelial superoxide anion production. Circulation 1995, 92:898-903. Rabbits fed 1% cholesterol for 1 month were returned to a normal diet for a further month. In this group, plasma cholesterol, elevated superoxide release and impaired response to endothelium-dependent vasodilators returned to normal. The major source of increased superoxide release in hypercholesterolemic vessels appeared to be the endothelium and not macrophages.
36. Mugge A, Elwell J, Peterson T, Hofmeyer T, Heistad D, Harrison D: Chronic treatment with polyethylene glycolated superoxide dismutase partially restores endothelium-dependent vascular relaxations in cholesterol-fed rabbits. Circ Res 1991, 69:1293-1300.
37. Pritchard KJ, Groszek L, Smalley DM, Sessa WC, Wu M, Villalon P, Wolin MS, Stemerman MB: Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res 1995, 77:510-518.
38. Deliconstantinos G, Villiotou V, Stavrides JC: Modulation of particulate nitric oxide synthase activity and peroxynitrite synthesis in cholesterol enriched endothelial cell membranes. Biochem Pharmacol 1995, 49:1589-1600. This study demonstrated that enrichment of endothelial cell membranes with unoxidized cholesterol can increase both NO* and superoxide generation.
39. Stralin P, Karlsson K, Johansson BO, Marklund SL: The interstitium of the human arterial wall contains very large amounts of extracellular superoxide dismutase. Arterioscler Thromb Vasc Biol 1995, 15:2032-2036. A comparison of the levels of SOD isoenzymes between species in normal arteries. The authors calculated that human SOD levels are sufficient to compete with NO* for superoxide generation under normal conditions, thereby limiting NO* inactivation and formation of peroxynitrite.
40. Fries DM, Penha RG, D'Amico EA, Abdalla DS, Monteiro HP: Oxidized low-density lipoprotein stimulates nitric oxide release by rabbit aortic endothelial cells. Biochem Biophys Res Commun 1995, 207:231-237.
41. Harrison DG, Venema RC, Arnal JF, Inoue N, Ohara Y, Sayegh H, Murphy TJ: The endothelial cell nitric oxide synthase: is it really constitutively expressed? Agents Actions Suppl 1995, 45:107-117.
42. Inoue N, Venema RC, Sayegh HS, Ohara Y, Murphy TJ, Harrison DG: Molecular regulation of the bovine endothelial cell nitric oxide synthase by transforming growth factor-beta 1. Arterioscler Thromb Vasc Biol 1995, 15:1255-1261.
43. Hirata K, Miki N, Kuroda Y, Sakoda T, Kawashima S, Yokoyama M: Low concentration of oxidized low-density lipoprotein and lysophosphatidylcholine upregulate constitutive nitric oxide synthase mRNA expression in bovine aortic endothelial cells. Circ Res 1995, 76:958-962
44. Zembowicz A, Tang JL, Wu KK: Transcriptional induction of endothelial nitric oxide synthase type III by lysophosphatidylcholine. J Biol Chem 1995, 270:17006-17010.
45. Liao JK, Shin WS, Lee WY, Clark SL: Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 1995, 270:319-324.
46. Bolton E, Jessup W, Stanley K, Dean R: Enhanced LDL oxidation by murine macrophage foam cells and their failure to secrete nitric oxide. Atherosclerosis 1994, 106:213-223.
47. Yang X, Cai B, Sciacca RR, Cannon PJ: Inhibition of inducible nitric oxide synthase in macrophages by oxidized low-density lipoproteins. Circ Res 1994, 74:318-328.
48. Thai SF, Lewis JG, Williams RB, Johnson SP, Adams DO: Effects of oxidized LDL on mononuclear phagocytes: inhibition of induction of four inflammatory cytokine gene RNAs, release of NO, and cytolysis of tumor cells. J Leukoc Biol 1995, 57:427-433.
49. Hamilton TA, Major JA, Chisolm GM: The effects of oxidized low density lipoproteins on inducible mouse macrophage gene expression are gene and stimulus dependent. J Clin Invest 1995, 95:2020-2027
50. Albina J: On the expression of nitric oxide synthase by human macrophages. Why no NO? J Leukoc Biol 1995, 58:643-649.
51. Luoma J, Särkioja T, Nikkari T, Ylä-Herttuala S: Macrophages express inducible nitric oxide synthase mRNA in human and rabbit atherosclerotic lesions. Atherosclerosis 1994, 109:102.
52. Jessup W, Leake D: Cell-mediated oxidation of lipoproteins. In Oxidative stress, lipoproteins and cardiovascular dysfunction. Edited by Rice-Evans C, Bruckdorfer K. London: Portland Press; 1995:99-129.
53. Jessup W, Mohr D, Gieseg SP, Dean RT, Stocker R: The participation of nitric oxide in cell free- and its restriction of macrophage-mediated oxidation of low-density lipoprotein. Biochim Biophys Acta 1992, 1180:73-82.
54. Yates MT, Lambert LE, Whitten PJ, McDonald I, Mano M, Ku G, Mao SJT: A protective role for nitric oxide in the oxidative modification of low density lipoproteins by mouse macrophages. FEBS Lett 1992, 309:135-138.
55. Jessup W, Dean RT: Autoinhibition of murine macrophage-mediated oxidation of low-density lipoprotein by nitric oxide synthesis. Atherosclerosis 1993, 101:145-155.
56. Malo-Ranta U, Ylä-Herttuala S, Metsa-Ketela T, Jaakkola O, Moilanen E, Vuorinen P, Nikkari T: Nitric oxide donor GEA 3162 inhibits endothelial cell-mediated oxidation of low-density lipoprotein. FEBS Lett 1994, 337:179-183.
57. Jessup W: Nitric oxide and macrophage-mediated oxidation of low-density lipoprotein. In Atherosclerosis. Edited by Woodford XF, Davignon J, Sniderman A. Amsterdam: Elsevier; 1994:209-212.
58. Hogg N, Struck A, Goss SP, Santanam N, Joseph J, Parthasarathy S, Kalyanaraman B: Inhibition of macrophage-dependent low density lipoprotein oxidation by nitric-oxide donors. J Lipid Res 1995, 36:1756-1762
59. Hogg N, Kalyanaraman B, Joseph J, Struck A, Partharasarathy S: Inhibition of low-density lipoprotein oxidation by nitric oxide. Potential role in atherogenesis. FEBS Lett 1993, 334:170-174.
60. Ischiropoulos H, al Mehdi A: Peroxynitrite-mediated oxidative protein modifications. FEBS Lett 1995, 364:279-282.
61. Radi R, Beckman JW, Bush KM, Freeman BA: Peroxynitrite induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys 1991, 288:481-487.
62. Graham A, Hogg N, Kalyanaraman B, O'Leary V, Darley-Usmar V, Moncada S: Peroxynitrite modification of low-density lipoprotein leads to recognition by the macrophage scavenger receptor. FEBS Lett 1993, 330:181-185.
63. Beckman JS, Ye YZ, Anderson PG, Chen J, Accavitti MA, Tarpey MM, White CR: Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol Chem Hoppe Seyler 1994, 375:81-88.
64. Zeiher AM, Fisslthaler B, Schray UB, Busse R: Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res 1995, 76:980-986.
65. Kolpakov V, Gordon D, Kulik T: Nitric oxide-generating compounds inhibit total protein collagen synthesis in cultured vascular smooth muscle cells. Circ Res 1995, 76:305-309.
66. Gauthier TW, Scalia R, Murohara T, Guo J-P, Lefer AM: Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995, 15:1652-1659.
67. Cayatte AJ, Palacino JJ, Horten K, Cohen RA: Chronic inhibition of nitric oxide production accelerated neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb 1994, 14:753-759.
68. Naruse K, Shimizu K, Muramatsu M, Toki Y, Miyazaki Y, Okumura K, Hashimoto H, Ito T: Long-term inhibition of NO synthesis promotes atherosclerosis in the hypercholesterolemic rabbit thoracic aorta. Arterioscler Thromb 1994, 14:746-452.
69. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME: Antiatherogenic effects of L-Arginine in the hypercholesterolemic rabbit. J Clin Invest 1992, 90:1168-1172.
70. Davies MG, Dalen H, Kim JH, Barber L, Svendsen E, Hagen PO: Control of accelerated vein graft atheroma with the nitric oxide precursor: L-arginine. J Surg Res 1995, 59:35-42.
71. Hill CH, Pullman EP, Starcher B, Shih JC: Dietary nitroprusside alleviates atherosclerosis in hypercholesterolemic Japanese quail (Coturnix coturnix japonica). Comp Biochem Physiol A Physiol 1995, 112:151-154.
72. Keaney JJ, Gaziano JM, Xu A, Frei B, Curran CJ, Shwaery GT, Loscalzo J, Vita JA: Low-dose alpha-tocopherol improves and high-dose alpha-tocopherol worsens endothelial vasodilator function in cholesterol-fed rabbits. J Clin Invest 1994, 93:844-851.
73. Parker R, Sabrah T, Cap M, Gill B: Relation of vascular oxidative stress, α-tocopherol and hypercholesterolemia to early atherosclerosis in hamsters. Arterioscler Thromb Vasc Biol 1995, 15:349-358. Hamsters on a moderately hypercholesterolemic diet deficient in antioxidants developed aortic lesions. These were prevented by α-tocopherol or probucol, whereas the same agents were not effective in more severe hypercholesterolemia. This suggests that hyperlipidemia may outweigh antioxidant effectiveness, which may explain some the variability seen in the efficacy of antioxidants as inhibition of atherosclerosis in experimental animal models.